Researchers at the Sanders-Brown Aging Center at the University of Kentucky have proposed a treatment for Alzheimer's disease with antibodies that activate the TREM2 receptor.
According to Qadin.Net, the study was published in the Journal of Neuroinflammation.
The technology allows to influence the neuroinflammation that causes the development of dementia in old age (dementia - a pathological syndrome characterized by mental retardation, loss of previously acquired knowledge and habits, quality of life to some extent, and the impossibility of acquiring new ones).
The new method has already been successfully tested in laboratory mice.